Presentation is loading. Please wait.

Presentation is loading. Please wait.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

Published byHerman Klausen Modified over 5 years ago

Similar presentations

Presentation on theme: "FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for."— Presentation transcript:

1 FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398.
FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. A, scatter plot of primary human gastric tumors showing the relationship between FGFR2 copy number and transcript expression (n = 49). The gastric tumors CHGA10 and GAM033 with FGFR2 gene amplification [(B) and (C), respectively] were grown subcutaneously in mice. Treatment with NVP-BGJ398 at the indicated doses started when average tumor volume was 150 to 180 mm3 and proceeded for up to 14 or 25 days. Tumor volume changes over the course of treatment are shown. Statistical analysis was conducted by 1-way ANOVA–Dunnett versus vehicle control (*, P < 0.001). D, tumor tissues from primary tumor model GAM033 treated with 15 mg/kg NVP-BGJ398 were recovered 3 hours after the last dose treatment and analyzed for FGFR2 Tyr-phosphorylation and Erk1/2 activation by Western blot analysis. Total FGFR2, Erk1/2, and β-tubulin Western blot analyses were conducted to monitor loading. Vito Guagnano et al. Cancer Discovery 2012;2: ©2012 by American Association for Cancer Research

Download ppt "FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for."

Similar presentations

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
CHK1 downregulation upon ERG overexpression.

CHK1 downregulation upon ERG overexpression.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.

A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.

EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.
miR‐205 modulates tumor cell sensitivity to MET‐TKIs

miR‐205 modulates tumor cell sensitivity to MET‐TKIs
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
eIF5A-PEAK1 signaling regulates KRAS protein expression.

eIF5A-PEAK1 signaling regulates KRAS protein expression.

Similar presentations

Ads by Google